All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Consequently, researchers have investigated the use of Chimeric Antigen Receptor-Modified (CAR) T-cell therapy as a possible immunotherapeutic mode of destroying leukemic cells. There have been investigational studies where CD33-directed CAR T-cell (CART-33) therapy has demonstrated antileukemic effects, however the tolerability of this therapy has generated some apprehension regarding its clinical potential. In this clinical trial, Q.S. Wang et al. of the Chinese PLA General Hospital analyzed the effects of CART-33 in a 41 year old male patient with refractory AML.
This clinical trial was registered at www.clinicaltrials.gov under the registration number NCT01864902. The results were published in Molecular Therapy in August 2015.
Although this trial took place in only one patient (more patients are being currently recruited), the results have provided some useful data regarding the safety and efficacy of CAR T-cell therapy. In terms of efficacy, there were some initial benefits observed within the first two weeks post-infusion. Unfortunately, the patient’s disease still progressed resulting in death 13 weeks after CART-33 infusions. Regarding the safety concerns, CAR T-cell therapy like chemotherapy has resulted in myelosuppression. In this report, the patient’s blood cell counts were adversely affected, however this did not result in infection.
With respect to the potential role of this novel therapy in AML management, the authors made the following recommendation “CART-33 infusions serve as a short-term problem-resolving approach that may be more suitable as a debulking and/or immune hit strategy for the treatment of relapsed and refractory AML patients and that this approach should be followed by an intensive chemotherapy regimen or hematopoietic stem cell transplantation.”
We conducted a clinical trial to assess the feasibility and efficacy of CD33-directed chimeric antigen receptor-modified T cells (CART-33) for the treatment of refractory acute myeloid leukemia (AML). A 41-year-old male patient with AML was enrolled and received a total of 1.12 × 109 autologous CART-33 cells, of which ~38% were transduced with CAR. The CART-33 infusion alone induced rigorous chills and fevers; drastic fluctuations of his pre-existing pancytopenia; elevated serum cytokine levels, including interleukin (IL)-6, IL-8, tumor necrosis factor-α, and interferon-γ; slight transient hyperbilirubinemia within 2 weeks; a subsequent intermittent moderate fever; and reversed fluctuation of the pancytopenia. A marked decrease of blasts in the bone marrow was observed on examination 2 weeks after therapy, and there was a gradual increase until florid disease progression occurred at 9 weeks after the cell infusion. These observations warrant further research on CART-33 treatment in refractory AML and may spur efforts to extend the CART-33-induced tumor burden to the preparation of other intensive strategies, such as hematopoietic stem cell transplantation. This study is registered at www.ClinicalTrials.gov as NCT01864902.
Subscribe to get the best content related to AML delivered to your inbox